In the claims:

Please cancel claims 2 and 3 without prejudice.

Please amend the claims as follows:

8. A compound selected from the group consisting of

(2-benzofuroyl)-Tyr-Chg-Arg-Pen-Pro-NH_2;

(2-benzofuroyl)-pAph-Chg-PalMe(3)-Pen(CH_2COOH)-Pro-NH_2;

Ac-pAph-Chg-Arg-Cys(CH_2COOH)-Pro-NH_2;

(Alloc)-pAph-Chg-Arg-Leu-Pro-NH_2;

(2-benzofuroyl)-pAph-Chg-Arg-Pen(CH_2COOH)-Pro-NH_2;

Ac-pAph-Chg-PalMe(3)-Pen(CH_2COOH)-Pro-NH_2;

Ac-pAph-Chg-Arg-Leu-Pro-NH_2; Ac-pAph-Chg-Arg-(HOOC-CH_2)Gly-Pro-NH_2;

Ac-pAph-Chg-Arg(HOOC-CH_2-CH_2)Gly-Pro-NH_2;

Ac-pAph-Chg-Arg-Gla-Pro-NH_2; Ac-pAph-Chg-Arg-Cys(CH_2-COOH)-Pro-NH_2;

Ac-Pal(4)Me-Chg-Arg-Leu-Pro-NH_2; Ac-(iBu)Nal(2)-Chg-Arg-Leu-Pro-NH_2;

Ac-Phe(p-$CONH_2$)-Chg-Arg-Leu-Pro-NH_2;

Ac-pAph-Chg-Arg-N[1(1,3-dicarboxy)propyl)]Gly-Pro-NH_2;

Ac-pAph-Chg-Dap(CH=N(CH_3)$_2$)-Leu-Pro-NH_2;

(2-quinolinoyl)-Phe(NH_2)-Chg-Arg-Leu-Pro-NH_2;

Ac-pAph-Chg-Arg-N(carboxymethyl)Gly-Pro-NH_2;

Ac-pAph-Chg-Arg-(carboxyethyl)Gly-Pro-NH_2; Ac-mAph-Chg-Arg-Leu-Pro-NH_2;

Alloc-pAph-Chg-PalMe(3)-Pen(CH_2COOH)-Pro-NH_2;

Ac-pAph-Chg-Arg-N[1(1,3-dicarboxy)propyl)]Gly-Pro-NH_2;

Ac-pAph-Ile-Arg-Leu-Pro-NH_2; Ac-Phe(pNH_2)-Chg-Arg-(Me)Leu-Pro-NH_2;

Ac-(Chx-CH_2)Tyr-Chg-Arg-Leu-Pro-NH_2;

(3-pyridoyl)-Phe(pNH_2)-Chg-Arg-Leu-Pro-NH_2;

(3-pyridoyl)-Nal(2)-Chg-Arg-Leu-Pro-NH_2;

Ac-Pal(4)Me-Chg-Pal(4)Me-Leu-Pro-NH_2; Alloc-pAph-Chg-Arg-Leu-Pro-NH_2;

(4-isoquinolinoyl)-Phe(pNH_2)-Chg-Arg-Leu-Pro-NH_2;

Ac-pAph-Cha-PalMe(3)-(Me)Leu-Pro-NH_2;

Ac-pAph-Chg-PalMe(3)-Leu-Pro-NH_2;

(2-naphythl-CH_2)Phe(pNH_2)-Chg-Arg-Leu-Pro-NH_2;

(5-pyrazinoyl)Nal(2)-Chg-Arg-Leu-Pro-NH_2;

(Benzoyl)-Phe(pNH_2)-Chg-Arg-Leu-Pro-NH_2;

Ac-(2-methylpentanyl)-Tyr-Ile-Arg-Leu-Pro-NH_2;

(2-pyridonyl)Phe(pNH_2)Chg-Arg-Leu-Pro-NH_2;

(Benzoyl)-Phe(pNH_2)-Chg-Arg-Leu-Pro-NH_2;

Ac-(2-methypentyl)Tyr-Ile-Arg-Leu-Pro-NH_2;

Ac-(iBu)Phe(pCN)-Chg-Arg-Leu-Pro-NH_2;

Ac-(2-methybutyl)Tyr-Ile-Arg-Leu-Pro-NH_2;

Ac-Phe(pNH_2)-Chg-Arg-Leu-Pro-NH_2;

Ac-Phe(pNH_2)-Chg-Arg-Leu-Hyp-NH_2; Ac-Tyr-Chg-Arg-Leu-Pro-NH_2;

(2-naphthylsulfonyl)-Phe(pNH_2)-Chg-Arg-Leu-Pro-NH_2;

(2-methylbenzyl)-Phe(pNH_2)-Chg-Arg-Leu-Pro-NH_2;

(2-benzofuroyl)-Phe(pNH_2)-Chg-Dab(CH=N$(CH_3)_2$)-Leu-Pro-NH_2;

Ac-(cyclopentenyl-CH_2)Tyr-Ile-Arg-Leu-Pro-NH_2;

Ac-Pal(4)Me-Chg-PalMe(3)-Leu-Pro-NH_2;

Ac-(iBu)-Phe(pNH_2)-Chg-Arg-Leu-Pro-NH_2; and

Ac-(Chx-CH_2)-Tyr-Ile-Arg-Leu-Pro-NH_2.

9. A compound selected from the group consisting of Ac-pAph-Chg-Arg-Leu-NH_2 and Ac-pAph-Chg-Arg-Leu.

10. A compound selected from the group consisting of (2-benzofuroyl)-pAph-Chg-PalMe(3)-NH_2 and Ac-(iBu)Phe(p NH_2)-Chg-Arg-NH_2.

11. A compound selected from the group consisting of

Alloc-pAph-Chg-PalMe(3)-NH_2; (2-quinolinoyl)-pAph-Chg-PalMe(3)-NH_2;

Ac-pAph-Chg-PalMe(3)-NH(1-methoxycarbonyl)-1-cyclohexyl;

Ac-pAph-Chg-Arg-NH_2; (2-pyridoyl)-pAph-Chg-PalMe(3)-NH_2;

$CF_3C(O)$-(iBu)Phe(pNH_2)-Chg-Arg-NH_2;

Ac-pAph-Chg-PalMe(3)-NH-(1-methoxycarbonyl)-1-cyclopentyl;

Ac-pAph-Chg-PalMe(3)-NH-(4-methoxycarbonyl-cyclohexyl)methyl;

Ac-pAph-Chg-PalMe(3)-NH-(3-thienyl-2-carboxylic acid methyl ester);

Ac-pAph-Chg-Arg-NH_2; $CF_3C(O)$-(iBu)Tyr-Chg-Arg-OH;

Ac-pAph-Chg-PalMe(3)-NH-(4-methoxycarbonyl-cyclohexyl)methyl;

Ac-pAph-Chg-PalMe(3)-NH_2; Ac-pAph-Chg-Pal(3)(CH_2COOH)-NH_2;

(2-quinolinecarboxy)-pAph-Chg-PalMe(3)-NH_2;

Ac-pAph-Chg-PalMe(3)-NH-(4-carboxycyclohexyl) methyl; and

$CF_3C(O)$(iBu)-Tyr-Ile-Arg-NH_2.

20. A compound selected from the group consisting of

Ac-*D*-pAph-Chg-Arg-Leu-Pro-NH_2; Ac-*D*-pAph-Chg-Arg-Gla-Pro-NH_2;

Ac-*D*-pAph-Chg-Arg-Cys(CH_2-COOH)-Pro-NH_2;

Ac-*D*-pAph-Chg-Arg-N(carboxymethyl)Gly-Pro-NH_2;

Ac-*D*-pAph-Chg-Arg-(carboxyethyl)Gly-Pro-NH_2;

Ac-*D*-pAph-Chg-Arg-N[1(1,3-dicarboxy)propyl)]Gly-Pro-NH_2;

Ac-*D*-pAph-Ile-Arg-Leu-Pro-NH_2; Alloc-*D*-pAph-Chg-Arg-Leu-Pro-NH_2;

Ac-*D*-pAph-Chg-PalMe(3)-Leu-Pro-NH_2; and Ac-*D*-pAph-Chg-Arg-NH_2.

25. A method of specifically inhibiting the activity of Factor Xa, comprising contacting the factor Xa with the compound as in claims 7, 8, 9, 10, 11, 20, 21, 22, or 23.